Andreas Brandl, PhD

Andreas Brandl, Beilhack lab, Multiple myeloma, tumor microenvironmentAfter finishing his studies in biology and completing his PhD-thesis in the Molecular Immunology Group of Prof. Dr. Hans-Martin Jäck at Erlangen University, Germany, he established a novel conditional knock-out mouse model as a postdoctoral fellow for an additional year in the same lab. Thereafter, he joined the Department of Plastic and Hand Surgery headed by Prof. Dr. med. Dr. h. c. Raymund E. Horch at the University Hospital of Erlangen-Nuremberg for two years. During this postdoctoral training time he gained profound insights in translational medical research and experience in working with primary endothelial cells, cancer cells and their interactions with bioactive materials. In 2013 Dr. Brandl was successfully funded with an ELAN-grant (Erlanger Leistungsbezogene Anschubfinanzierung und Nachwuchsförderung) of the faculty of medicine. Following his interest in immunology Dr. Brandl returned to the field of tumor immunology and joined the group of Prof. Beilhack at Würzburg University. In 2015 he was awarded with a grant from the Senator Kurt and Inge Schuster-Foundation to support his current cancer immunology research. Currently he is principal investigator within the DFG funded µbone research consortium “Colonisation and Interactions of Tumor Cells within the Bone Microenvironment“ (SPP 2084). His research focuses on the interactions of multiple myeloma cells with different subsets of immune cells and endothelial cells within the bone marrow tumor niche environment. As the lab biosafety manager he is responsible for the coordination of multiple research activities, logistics and organization within the group.



Dr. Andreas Brandl

Tel:   +49-931-201 44055 (office)

Tel:   +49-931-201 27637 (lab)



Brandl A, Solimando AG, Mokhtari Z, Tabares P, Medler P, Manz H, Da Via M, Croci GA, Kurzwart M, Thusek S, Schneider T, Ebert R, Jakob F, Einsele H, Beilhack A. (2021). Junctional Adhesion Molecule-C expression specifies a CD138low/neg multiple myeloma cell population in mice and men. Blood Advances, Blood Advances, 6(7):2195-2206

Dahlhoff J, Manz H, Steinfatt T, Delgado-Tascon J, Seebacher E, Schneider T, Wilnit A, Mokhtari Z, Tabares P, Böckle D, Rasche L, Kortüm KM, Lutz MB, Einsele H, Brandl A, Beilhack A. (2022). Transient regulatory T cell targeting triggers immune control of multiple myeloma and prevents disease progression. Leukemia, 36(3):790-800.

Solimando AG, Da Vià MC, Leone P, Borrelli P, Croci GA, Tabares P, Brandl A, Di Lernia G, Bianchi FP, Tafuri S, Steinbrunn T, Balduini A, Melaccio A, De Summa S, Argentiero A, Rauert-Wunderlich H, Frassanito MA, Ditonno P, Henke E, Klapper W, Ria R, Terragna C, Rasche L, Rosenwald A, Kortüm KM, Cavo M, Ribatti D, Racanelli V, Einsele H, Vacca A, Beilhack A. (2021). Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression. Haematologica 106(7):1943-1956.

Röhner L, Ng YLD, Scheffold A, Lindner S, Köpff S, Brandl A, Beilhack A, Krönke J. (2021). Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn(I391V). Exp Hematol.  93:61-69.e4

Rummler M, Ziouti F, Bouchard AL, Brandl A, Duda N, Bogen B, Beilhack A, Lynch ME, Jundt F*, Willie BM*. (2020). Mechanical loading prevents bone destruction and exerts anti-tumor effects in the MOPC315.BM.Luc model of myeloma bone disease. Acta Biomaterialia 119:247-258.

Horvat S, Vogel P, Kampf T, Brandl A, Alshamsan A, Alhadlaq HA, Ahamed M, Albrecht K, Behr VC, Beilhack A, Groll J. (2020). Crosslinked Coating Improves the Signal‐to‐Noise Ratio of Iron Oxide Nanoparticles in Magnetic Particle Imaging (MPI). ChemNanoMat 6(5): 755-758.

Solimando AG*, Brandl A*, Mattenheimer K, Graf C, Ritz M, Ruckdeschel A, Stühmer T, Mokhtari Z, Rudelius M, Dotterweich J, Bittrich M, Desanti V, Ebert R, Trerotoli P, Frassanito MA, Rosenwald A, Vacca A, Einsele H, Jakob F, Beilhack A. (2017). JAM-A as a prognostic factor and new therapeutic target in multiple myeloma. Leukemia 32(3):736-743(*contributed equally)

Müller E, Bauer S, Stühmer T, Mottok A, Scholz CJ, Steinbrunn T, Brünnert D, Brandl A, Schraud H, Kreßmann S, Beilhack A, Rosenwald A, Bargou RC, Chatterjee M. (2017). Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS. Leukemia 31:922-933.

Brandl A, Daum P, Brenner S, Schulz SR, Yap DYH, Bösl MR, Wittmann J, Schuh W, Jäck HM. (2016). The microprocessor component, DGCR8, is essential for early B-cell development in mice. Eur J Immunol 46:2710-2718.

Chopra M, Biehl M, Steinfatt T, Brandl A, Kums J, Amich J, Vaeth M, Kuen J, Holtappels R, Podlech J, Mottok A, Kraus S, Jordán Garrote AL, Bäuerlein CA, Brede C, Ribecchini E, Fick A, Seher A, Polz J, Ottmüller K, Baker J, Nishikii H, Ritz M, Mattenheimer K, Schwinn S, Winter T, Schäfer V, Krappmann S, Einsele H, Mueller TD, Reddehase MJ, Lutz MB, Männel DN, Berberich-Siebelt F, Wajant H, Beilhack A. (2016). Exogenous TNFR2 activation protects from acute GvHD by induction of host Treg expansion. J Exp Med 213:18811900.

Dotterweich J, Tower RJ, Brandl A, Müller M, Hofbauer LC, Beilhack A, Ebert R, Glüer CC, Tiwari S, Schütze N, Jakob F. (2016). The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease. PLoS One. 11(5):e0155087.

Hoppe A, Brandl A, Bleiziffer O, Arkudas A, Horch RE, Jokic B, Janackovic D, Boccaccini AR. (2015). In vitro cell response to Co-containing 1,393 bioactive glass. Mater Sci Eng C Mater Biol Appl. 57:157-163.

Chopra M, Brandl A, Siegmund D, Mottok A, Schäfer V, Biehl M, Kraus S, Bäuerlein CA, Ritz M, Mattenheimer K, Schwinn S, Seher A, Grabinger T, Einsele H, Rosenwald A, Brunner T, Beilhack A, Wajant H. (2015). Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD. Blood. 126(4):437-444.

Porstner M, Winkelmann R, Daum P, Schmid J, Pracht K, Côrte-Real J, Schreiber S, Haftmann C, Brandl A, Mashreghi MF, Gelse K, Hauke M, Wirries I, Zwick M, Roth E, Radbruch A, Wittmann J, Jäck HM. (2015). miR-148a promotes plasma cell differentiation and targets the germinal center transcription factors Mitf and Bach2. Eur J Immunol. 45(4):1206-1215.

Buehrer G, Balzer A, Arnold I, Beier JP, Koerner C, Bleiziffer O, Brandl A, Weis C, Horch RE, Kneser U, Arkudas A. (2015). Combination of BMP2 and MSCs significantly increases bone formation in the rat arterio-venous loop model. Tissue Eng Part A. 21(1-2):96-105.

Yuan Q, Bleiziffer O, Boos AM, Sun J, Brandl A, Beier JP, Arkudas A, Schmitz M, Kneser U, Horch RE. (2014). PHDs inhibitor DMOG promotes the vascularization process in the AV loop by HIF-1a up-regulation and the preliminary discussion on its kinetics in rat. BMC Biotechnol. 14:112.

Rath SN, Brandl A, Hiller D, Hoppe A, Gbureck U, Horch RE, Boccaccini AR, Kneser U. (2014). Bioactive copper-doped glass scaffolds can stimulate endothelial cells in co-culture in combination with mesenchymal stem cells. PLoS One. 9(12):e113319.

Brandl A, Quan Yuan, Anja M. Boos, Justus P. Beier, Andreas Arkudas, Ulrich Kneser, Raymund E. Horch, Oliver Bleiziffer. (2014). A Novel Early Precursor Cell Population from Rat Bone Marrow Promotes Angiogenesis in vitro. BMC Cell Biol. 15:12.

Weis C, Blank F, West A, Black G, Woodward RC, Carroll MR, Mainka A, Kartmann R, Brandl A, Bruns H, Hallam E, Shaw J, Murphy J, Teoh WY, Aifantis KE, Amal R, House M, Pierre TS, Fabry B. (2014). Labeling of cancer cells with magnetic nanoparticles for magnetic resonance imaging. Magn Reson Med. 71(5):1896-1905.

Rath SN, Nooeaid P, Arkudas A, Beier JP, Strobel LA, Brandl A, Roether JA, Horch RE, Boccaccini AR, Kneser U. (2013). Adipose-Derived and Bone Marrow-Derived Mesenchymal Stem Cells Display Different Osteogenic Differentiation Patterns in 3D Bioactive Glass Based Scaffolds. J Tissue Eng Regen Med. 2013 Dec 3. doi: 10.1002/term.1849. [Epub ahead of print]

Brenner S, Drewel D, Steinbart T, Weisel F, Härtel E, Pötzsch S, Welzel H, Brandl A, Yu P, Mudde GC, Schweizer A, Nitschke L, Winkler TH. (2011). A hypomorphic IgH-chain allele affects development of B-cell subsets and favours receptor editing. EMBO J. 30(13):2705-2718.

Brandl A, Wittmann J and Jack HM. (2011) A facile method to increase titers of miRNA-encoding retroviruses by inhibition of the RNaseIII enzyme Drosha. Eur J Immunol. 41(2):549-551.

Hayer S, Polzer K, Brandl A, Zwerina J, Kireva T, Smolen JS, and Schett G. (2008). B-Cell Infiltrates Induce Endosteal Bone Formation in Inflammatory Arthritis. J Bone Miner Res. 23:1650–1660.